drugset / Trial / NCT00801931
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.
Timeline
- Start
- 2007-09-06
- Primary completion
- 2009-05-05
- Completion
- 2009-05-05
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Subject | Alemtuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Fludarabine | Small molecule | — | Intravenous |
| Subject | Melphalan | Small molecule | 1.5 mg/kg | Intravenous |
| Subject | Melphalan | Small molecule | 45 mg/m2 | Intravenous |
| Subject | Thiotepa | Other / unclassified | — | Intravenous |
| Subject | rabbit anti-thymocyte globulin | Protein / enzyme biologic | — | Intravenous |
| Background | Phenytoin | Unknown | — | Intravenous |